ArticleFrontiers in immunology2025
The role of CTGF and MFG-E8 in the prognosis assessment of SCAP: a study combining machine learning and nomogram analysis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe Community-Acquired Pneumonia (SCAP) is a serious global health issue with high incidence and mortality rates. In recent years, the role of biomarkers such as Connective Tissue Growth Factor (CTGF) and Milk Fat Globule-Epidermal Growth Factor 8 (MFG-E8) in disease diagnosis and prognosis has increasingly gained attention. However, their specific functions in SCAP have still remained unclear. By conducting a prospective analysis, this study has explored the relationship between these two proteins and the diagnosis and mortality of SCAP patients. Additionally, founded on comparing the applications of machine learning and nomograms as predictive models in forecasting the 28-day mortality risk of SCAP patients, this paper has discussed their performance in different medical scenarios to provide more accurate treatment options and improve prognosis. Methods: 198 patients diagnosed with SCAP, 80 patients with CAP and 80 healthy individuals were encompassed in the study. Demographic characteristics, clinical features and biomarkers were extracted. The ELISA method was employed to measure the levels of MFG-E8 and CTGF in the three groups. The 28-day mortality of SCAP patients was tracked. Eleven models, including XGBoost and CatBoost, were used as prediction models and compared with a nomogram. And 14 scoring methods, like F1 Score and AUC Score, were used to evaluate the prediction models. Results: Compared to healthy controls, SCAP patients had higher serum levels of CTGF and MFG-E8, suggesting that these biomarkers are associated with poor prognosis. Compared to CAP patients, SCAP patients had lower levels of MFG-E8 and higher levels of CTGF. In the deceased group of SCAP patients, their CTGF levels were higher and MFG-E8 levels were lower. Using the CatBoost model for prediction, it performed the best, with key predictive features including Oxygenation Index, cTnT, MFG-E8, Dyspnea, CTGF and PaCO2. Conclusion: This study has highlighted the critical role of clinical and biochemical markers such as CTGF and MFG-E8 in assessing the severity and prognosis of SCAP. The CatBoost model has shown the significant potential in predicting mortality risk by virtue of its unique algorithmic advantages and efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.